Long-Term Outcomes With Isatuximab-Carfilzomib-Dexamethasone (Isa-Kd) in Relapsed Multiple Myeloma (MM) Patients (pts) With 1q21+Status: Updated Results from the Phase 3 IKEMA Study

被引：0

作者：

Facon, Thierry ^{[1
]}

Moreau, Philippe ^{[2
]}

Spicka, Ivan ^{[3
]}

Suzuki, Kenshi ^{[4
]}

Yong, Kwee ^{[5
]}

Mikhael, Joseph ^{[6
]}

Fukao, Taro ^{[7
]}

Bisht, Kamlesh ^{[7
]}

Armstrong, Nicole ^{[8
]}

Mace, Sandrine ^{[9
]}

Risse, Marie-Laure ^{[10
]}

Martin, Thomas ^{[11
]}

机构：

[1] Lille Univ Hosp, Dept Hematol, Lille, France

[2] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France

[3] Charles Univ & Gen Hosp, Fac Med 1, Dept Hematol, Prague, Czech Republic

[4] Japanese Red Cross Med Ctr, Myeloma Amyloidosis Ctr, Tokyo, Japan

[5] Univ Coll Hosp, Dept Haematol, London, England

[6] City Hope Canc Ctr, Translat Genom Res Inst, Phoenix, AZ USA

[7] Sanofi, Global Oncol, Cambridge, MA USA

[8] Sanofi, Global Med Affairs, Cambridge, MA USA

[9] Sanofi, Res & Dev, Chilly Mazarin, France

[10] Sanofi, Res & Dev, Vitry Sur Seine, France

[11] Univ Calif San Francisco, Med Ctr, San Francisco, CA USA

来源：

关键词：

1q21; IKEMA; isatuximab; carfilzomib; dexamethasone; multiple myeloma; phase III;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-248

引用

页码：S484 / S485

页数：2